Publication Name	World Journal of Gastroenterology
Manuscript ID	5049
Country	Italy

Received	2013-08-12 11:23
Peer-Review Started	2013-08-12 15:35
First Decision by Editorial Office Director
Return for Revision	2013-09-05 14:14
Revised
Publication Fee Transferred
Second Decision by Editor	2013-12-13 13:57
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-12-13 14:44
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-12-31 15:06
Publish the Manuscript Online	2014-01-19 14:17

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment
Manuscript Source	Invited Manuscript
All Author List	Girolamo Ranieri, Ilaria Marech, Vito Lorusso, Veronica Goffredo, Angelo Paradiso, Domenico Ribatti and Cosmo Damiano Gadaleta
Funding Agency and Grant Number
Corresponding Author	Girolamo Ranieri, MD, Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Cancer Institute “Giovanni Paolo Ⅱ”, Via Orazio Flacco 65, 70124 Bari, Italy. giroran@tiscalinet.it
Key Words	Hepatocellular carcinoma; Molecular targeting agents; Angiogenesis; Chemoembolization therapeutic; Radiofrequency treatment; Sorafenib
Core Tip	The outcome of patients (with early or intermediate stage according to Barcelona Clinic Liver Cancer) treated with loco-regional approach alone [radiofrequency ablation (RFA) or transarterial chemoembolization (TACE)] is disappointing because the rebound of vascular endothelia growth factors induced by tissue hypoxia. On this basis there is a strong preclinical background to associate TACE or RFA with anti-angiogenic agents. We summarized the crucial role of angiogenesis and the pathways involved in hepatocellular cancer progression, underscoring the consequences of pro- and anti-angiogenic factors produced after loco-regional therapy. We explored preclinical and clinical results of trials combining molecular targeting agents plus TACE or RFA.
Publish Date	2014-01-19 14:17
Citation	Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol 2014; 20(2): 486-497
URL	http://www.wjgnet.com/1007-9327/full/v20/i2/486.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i2.486

Full Article (PDF)	WJG-20-486.pdf
Full Article (Word)	WJG-20-486.doc
Manuscript File	5049-Review.docx
Answering Reviewers	5049-Answering reviewers.pdf
Copyright License Agreement	5049-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5049-Language certificate.pdf
Peer-review Report	5049-Peer reviews.pdf
Scientific Editor Work List	5049-Scientific editor work list.doc